טוען...
Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer
With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment str...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Chinês |
| יצא לאור: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-04-01
|
| סדרה: | Chinese Journal of Lung Cancer |
| נושאים: | |
| גישה מקוונת: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.07 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|